Skip to main content
Caplight Logo









Luzitin

Luzitin

Private
CoimbraHealthcare & Life Scienceshttps://www.bluepharmagroup.com/

Last Round

Growth Equity

Dec 19, 2023

Total Funding Raised

$32.84M

Company Overview

Luzitin is a drug discovery company that develops innovative photosensitizing compounds intended for photodynamic therapy and photo diagnosis.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

photodynamic therapyPDTphotosensitizersoncologyclinical-stage pharmadrug developmentRedaporfinsolid tumor treatmentpharma licensingphotodiagnosisPDxuniversity spin-offbiliary tract canceracne treatment

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Luzitin Comparables

Compare Luzitin with similar companies based on industry and business-model similarity.

Luzitin comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
biolitec Holding GmbH & Co KG
80%
ImPact Biotech
78%
Theralase Technologies Inc.
78%

Luzitin Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Growth EquityDec 19, 2023
SeedOct 7, 2010

Key People

Founding team and executive leadership

Paulo Barradas Rebelo

CEO

Executive Team

Sergio Simoes

Chief Executive Officer, Member Of The Board, Vice President

Executive Team

Catarina Xavier

Chief Financial Officer

Executive Team

Sofia Ferreira

Chief Operating Officer

Executive Team

Luzitin Investors

Notable investors and investment history

Luzitin investors
InvestorRounds
InovCapitalSeed
C2 Capital PartnersGrowth Equity

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 7, 2026

    Monthly visitors increased 108% MoM, reaching 9.3K.

  • Jul 2, 2025

    Monthly visitors grew 72% MoM, reaching 5K.

Luzitin Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Luzitin Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Luzitin's valuation, stock price, and market status.

Firmographic Details

HeadquartersCoimbra
Employee Range525
Year Founded2010
Last FundingDec 19, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?